BGT007H cells for advanced digestive cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new cell therapy called BGT007H for people with advanced digestive tract cancers (esophagus, stomach, pancreas, or colon) that have not responded to or stopped working after at least two prior treatments. The goal is to see if this therapy can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 70 years old.
- You must have a digestive tract cancer (esophagus, stomach, pancreas, or colorectum) that has spread or returned and did not respond to at least two prior standard treatments.
- A sample of your tumor (from a biopsy or stored tissue) must show a specific protein target that the therapy is designed to attack.
- You must have at least one tumor that can be measured on a scan.
- You need to be in fairly good general health, with adequate organ function (like blood counts, liver, and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called BGT007 for people with advanced cancers of the digestive system (esophagus, stomach, pancreas, or colon) that have not responded to standard treatments. The therapy uses your own immune cells, modified to target a protein on your cancer cells.
This trial tests an experimental cell therapy called BGT007 for people with advanced pancreatic or colorectal cancer that has not responded to standard treatments. The therapy uses your own immune cells, which are collected, modified, and given back to you to fight the cancer.
This trial tests a new type of cell therapy (BGT007H cells) for people with advanced gastrointestinal cancers that have not responded to at least two standard treatments. The therapy uses your own immune cells that are modified to target and attack the cancer.
This trial tests a new cell therapy (BGT007H) for people with advanced pancreatic cancer that has not responded to earlier treatments. The goal is to see if it is safe and can help shrink or control the cancer.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to target a protein (Claudin18.2) found on some stomach and pancreatic cancer cells. The goal is to see if these specially designed cells can shrink tumors and slow the cancer's growth.
This trial tests a new type of cell therapy that uses your own immune cells, modified to target proteins found on some stomach cancer cells. It is for people with advanced stomach cancer that has not responded to standard treatments.
Hear when a new Digestive Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.